Skip to main content


We're creating a new version of this page. See preview

  • Meeting abstract
  • Open Access

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care19971 (Suppl 1) :P040

  • Published:


  • Lipid
  • Liver Function
  • Thrombocytopenia
  • Emergency Medicine
  • Lower Incidence


To evaluate the differences in administered in a lipid emulsion compared to amphotericin B (AmpoB) in dextrose 5%, for the treatment of Candida albicans infection.

Sixty consecutive critically ill patients with confirmed or suspected Candida infection received AmphoB (1 mg/kg/24 h) administered randomly in either dextrose 5% (group A) or in lipid emulsion (20% Intralipid®) (group B).

Measurements and main results

Clinical tolerance (fever, chills, hemodynamics), liver function tests, electrolytes and coagulation profile were evaluated. Patients receiving AmphoB in lipid emulsion experienced a lower incidence of drug-associated fever (61.4% versus 5.8%, P < 0.003), rigors (54% versus 8.5%, P < 0.004), hypotension (17% versus 0%) and nephrotoxicity. Significant thrombocytopenia (264,500 ± 71,460/mm3 to 163,570 ± 34,450/mm3, P < 0.01), not associated with active bleeding, occurred with AmphoB-lipid emulsion but not with the dextrose regimen.


Treatment with AmphoB-lipid emulsion of critically ill patients with Candida infection seems to be safer and as effective as the conventional mode of administration.

Authors’ Affiliations

Departments of Anesthesiology and Surgery, Sourasky Medical Center, Tel Aviv University, Tel-Aviv, Israel


© Current Science Ltd 1997